Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery

被引:474
作者
Giacchetti, S
Itzhaki, M
Gruia, G
Adam, R
Zidani, R
Kunstlinger, F
Brienza, S
Alafaci, E
Bertheault-Cvitkovic, F
Jasmin, C
Reynes, M
Bismuth, H
Misset, JL
Lévi, F
机构
[1] Hop Paul Brousse, Lab Rythmes Biol & Chronotherapeut, ICIG,Ctr Chronotherapie,Serv Oncol Med, Federat Malad Sanguines Immunitaires & Tumorales, F-94807 Villejuif, France
[2] Hop Paul Brousse, Serv Anat Pathol, F-94807 Villejuif, France
关键词
chronotherapy; colorectal cancer; liver metastases; oxaliplatin; surgery; survival;
D O I
10.1023/A:1008347829017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Context: Long-term survival of patients with metastatic colorectal cancer has been achieved only in patients who underwent complete resection of metastases. Such surgery could be performed in a greater proportion of patients if effective chemotherapy could downstage previously unresectable metastases. This approach has been limited by the low tumor response rate achieved with conventional chemotherapy. Objective: We studied the outcome of patients with initially unresectable liver metastases from colorectal cancer treated with a three-drug chemotherapy regimen followed by liver metastases surgery whenever possible. Patients and methods: From March 1988 to June 1994, 151 patients with colorectal liver metastases were considered initially unresectable because of large tumor size (> 5 cm), multinodular (> 4) or ill-located metastases. All patients received fully ambulatory chemotherapy with 5-fluorouracil, leucovorin and oxaliplatin (chronotherapy in 83% of them). They were periodically reassessed for surgery by a joint medico-surgical team. Results: In 151 patients, the size of liver metastases decreased by > 50% in 89 patients (59%) and median overall survival was 24 months (95% confidence interval (95% CI): 19-28 months), with 28% surviving at five years (20%-35%). Surgery with curative intent was attempted in 77 patients (51%), complete resection of liver metastases was achieved in 58 patients (38%). The median survival of the 77 operated patients was 48 months (25-71), with a five-year survival rate of 50% (38-61). Conclusion: This new strategy of combining effective chemotherapy with surgery apparently altered the natural history of unresectable colorectal cancer metastases.
引用
收藏
页码:663 / 669
页数:7
相关论文
共 52 条
[21]  
GAYOWSKI TJ, 1994, SURGERY, V116, P703
[22]   EXPECTANCY OR PRIMARY CHEMOTHERAPY IN PATIENTS WITH ADVANCED ASYMPTOMATIC COLORECTAL-CANCER - A RANDOMIZED TRIAL [J].
GLIMELIUS, B ;
PAHLMAN, L ;
GRAF, W ;
ADAMI, HO ;
TVEIT, K ;
HANSEN, J ;
LILJEGREN, G ;
DOMELoF, L ;
LJUNGQVIST, U ;
BERGMAN, L ;
ENANDER, LK ;
UNDERSKOG, I ;
SoDERBERG, M ;
JoNSSON, PE ;
HAFSTRoM, L ;
HEUMAN, R ;
ATHLIN, L ;
SASSNER, P ;
SELLSTRoM, H .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (06) :904-911
[23]   HEPATIC RESECTION OF METASTASIS FROM COLORECTAL-CARCINOMA - MORBIDITY, MORTALITY, AND PATTERN OF RECURRENCE [J].
HOLM, A ;
BRADLEY, E ;
ALDRETE, JS .
ANNALS OF SURGERY, 1989, 209 (04) :428-434
[24]   HEPATIC RESECTION FOR METASTASES FROM COLORECTAL-CARCINOMA - A SURVIVAL ANALYSIS [J].
JATZKO, GR ;
LISBORG, PH ;
STETTNER, HM ;
KLIMPFINGER, MH .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (01) :41-46
[25]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[26]  
KOHNEWOMPNER CH, 1992, SEMIN ONCOL, V19, P105
[27]   A MULTIFACTORIAL ANALYSIS OF PROGNOSTIC FACTORS IN PATIENTS WITH LIVER METASTASES FROM COLORECTAL-CARCINOMA [J].
LAHR, CJ ;
SOONG, SJ ;
CLOUD, G ;
SMITH, JW ;
URIST, MM ;
BALCH, CM .
JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (11) :720-726
[28]  
LEVI F, 1992, CANCER, V69, P893, DOI 10.1002/1097-0142(19920215)69:4<893::AID-CNCR2820690410>3.0.CO
[29]  
2-X
[30]   CHRONOMODULATION OF CHEMOTHERAPY AGAINST METASTATIC COLORECTAL-CANCER [J].
LEVI, F ;
GIACCHETTI, S ;
ADAM, R ;
ZIDANI, R ;
METZGER, G ;
MISSET, JL .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (7-8) :1264-1270